---
figid: PMC7418786__gr3_lrg
figtitle: Growth Factor Receptor Signaling Inhibition Prevents SARS-CoV-2 Replication
organisms:
- Homo sapiens
- Severe acute respiratory syndrome coronavirus 2
pmcid: PMC7418786
filename: gr3_lrg.jpg
figlink: pmc/articles/PMC7418786/figure/fig3/
number: F3
caption: Drug-Target Phosphoprotein Network Analysis Identifies Growth Factor Signaling
  as Central Hub for Possible Intervention by Repurposed Drugs(A) Proteins significantly
  increased in phosphorylation (FC > 1, FDR < 0.05) were subjected to ReactomeFI pathway
  analysis and overlaid with a network of US Food and Drug Administration (FDA)-approved
  drugs. The network was filtered for drugs and drug targets only, to identify pathways
  that could be modulated by drug repurposing. The red lines indicate drug-target
  interactions, and the gray lines protein-protein interactions. The identified drugs
  are represented with yellow rectangles, while proteins are represented by blue circles.(B)
  Search across all proteins with significant phosphorylation changes upon SARS-CoV-2
  infection for proteins related to the EGFR pathway. The STRING network highlights
  all of the proteins annotated for EGFR signaling and their direct interaction neighbors.
  The red lines indicate direct EGFR interactions, the black lines indicate interactions
  between pathway members, and the gray lines represent filtered interactions to represent
  the whole network.(C) Pathway representation of proteins identified in (B) to be
  direct functional interactors of EGFR, according to the STRING interaction database
  (confidence cutoff 0.9). The phosphorylation changes of all significantly regulated
  sites are indicated by color-coded pie charts. Red indicates upregulation and blue
  indicates downregulation.See also .
papertitle: Growth Factor Receptor Signaling Inhibition Prevents SARS-CoV-2 Replication.
reftext: Kevin Klann, et al. Mol Cell. 2020 Oct 1;80(1):164-174.e4.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8501823
figid_alias: PMC7418786__F3
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC7418786__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7418786__gr3_lrg.html
  '@type': Dataset
  description: Drug-Target Phosphoprotein Network Analysis Identifies Growth Factor
    Signaling as Central Hub for Possible Intervention by Repurposed Drugs(A) Proteins
    significantly increased in phosphorylation (FC > 1, FDR < 0.05) were subjected
    to ReactomeFI pathway analysis and overlaid with a network of US Food and Drug
    Administration (FDA)-approved drugs. The network was filtered for drugs and drug
    targets only, to identify pathways that could be modulated by drug repurposing.
    The red lines indicate drug-target interactions, and the gray lines protein-protein
    interactions. The identified drugs are represented with yellow rectangles, while
    proteins are represented by blue circles.(B) Search across all proteins with significant
    phosphorylation changes upon SARS-CoV-2 infection for proteins related to the
    EGFR pathway. The STRING network highlights all of the proteins annotated for
    EGFR signaling and their direct interaction neighbors. The red lines indicate
    direct EGFR interactions, the black lines indicate interactions between pathway
    members, and the gray lines represent filtered interactions to represent the whole
    network.(C) Pathway representation of proteins identified in (B) to be direct
    functional interactors of EGFR, according to the STRING interaction database (confidence
    cutoff 0.9). The phosphorylation changes of all significantly regulated sites
    are indicated by color-coded pie charts. Red indicates upregulation and blue indicates
    downregulation.See also .
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - OXSR1
  - AAK1
  - PRKD2
  - CDC42BPB
  - EPHX2
  - MAPK14
  - SRC
  - FGR
  - FYN
  - YES1
  - EGFR
  - HDAC1
  - RPS6KA4
  - MAP2K2
  - SIK3
  - STK3
  - STK24
  - CLK3
  - PXN
  - PXDN
  - PAG1
  - ITSN2
  - BIN1
  - CTNND1
  - TMX2-CTNND1
  - FNBP1L
  - PACSIN3
  - ITSN1
  - REPS1
  - EPS15
  - WASL
  - ARHGEF7
  - NCK1
  - ACTA1
  - ACTA2
  - ACTB
  - ACTC1
  - ACTG1
  - ACTG2
  - IQSEC1
  - CTTN
  - EPN1
  - EPS8
  - PIK3C2A
  - CBL
  - AGFG1
  - ABI1
  - SOS1
  - HGS
  - CLTA
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - KRAS
  - HRAS
  - NRAS
  - EPS15L1
  - DAB2
  - STAMBP
  - ARRB1
  - GAK
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK8
  - MAPK9
  - MAPK10
  - EIF2AK2
  - EIF2AK3
  - PRKCA
  - PTPN1
  - YAP1
  - STAT3
  - CTRL
  - CALCR
  - SLC31A1
  - CCDC174
  - Axitinib
  - OPazopanib
  - O RIPK2O
  - OAfatinib
  - Vandetanib
  - Imatinib
  - O
  - Erotinib
  - Dexamethasone
  - Sorafenib
  - Prednisone
  - Romidepsin
  - Bosutinib
  - Docetaxel
  - Ibrutinib
  - Lapatinib
  - Ruxolitinib
  - Tranetinib
  - SARS-COV-2
---
